Literature DB >> 30305330

Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease.

Matthieu Turpin1,2,3, Christelle Chantalat-Auger1,4,5, Florence Parent1,2,3,5, Françoise Driss1,4, François Lionnet6, Anoosha Habibi7,8, Bernard Maître9, Alice Huertas1,2,3, Xavier Jaïs1,2,3, Jason Weatherald10,11, David Montani1,2,3, Olivier Sitbon1,2,3, Gérald Simonneau1,2,3, Fréderic Galactéros7,8, Marc Humbert1,2,3, Pablo Bartolucci7,8, Laurent Savale1,2,3.   

Abstract

The long-term effects of chronic blood exchange transfusions (BETs) on pre-capillary pulmonary hypertension complicating sickle cell disease (SCD) are unknown.13 homozygous SS SCD patients suffering from pre-capillary pulmonary hypertension and treated by chronic BETs were evaluated retrospectively. Assessments included haemodynamics, New York Heart Association Functional Class (NYHA FC), 6-min walk distance (6MWD) and blood tests.Before initiating BETs, all patients were NYHA FC III or IV, median (range) 6MWD was 223 (0-501) m and median (range) pulmonary vascular resistance (PVR) was 3.7 (2-12.5) Wood Units. After a median number of 4 BET sessions, all patients had improved to NYHA FC II or III. Significant improvements in haemodynamics were observed, including a decrease in PVR (p=0.01). There was a trend to higher 6MWD (p=0.09). Median (range) follow-up time after initiation of BETs was 25 (6-53) months. During this period, two patients decided to stop BETs. One of them died from acute right heart failure and the other experienced worsening pulmonary hypertension. Two other patients died during follow-up at 25 and 54 months after BET initiation.Chronic BETs may be a potential therapeutic option in pre-capillary pulmonary hypertension complicating SCD, leading to significant clinical and haemodynamic improvements. These data must be confirmed in a prospective study.
Copyright ©ERS 2018.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30305330     DOI: 10.1183/13993003.00272-2018

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

Review 1.  Sickle Cell Disease-Induced Pulmonary Hypertension: A Review of Pathophysiology, Management, and Current Literature.

Authors:  Abu Baker Sheikh; Adeel Nasrullah; Erick Daniel Lopez; Mian Tanveer Ud Din; Shazib Sagheer; Ishan Shah; Nismat Javed; Rahul Shekhar
Journal:  Pulse (Basel)       Date:  2021-09-23

2.  Xanthine Oxidase Drives Hemolysis and Vascular Malfunction in Sickle Cell Disease.

Authors:  Heidi M Schmidt; Katherine C Wood; Sara E Lewis; Scott A Hahn; Xena M Williams; Brenda McMahon; Jeffrey J Baust; Shuai Yuan; Timothy N Bachman; Yekai Wang; Joo-Yeun Oh; Samit Ghosh; Solomon F Ofori-Acquah; Jeffrey D Lebensburger; Rakesh P Patel; Jianhai Du; Dario A Vitturi; Eric E Kelley; Adam C Straub
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-12-03       Impact factor: 8.311

3.  Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report.

Authors:  A Parker Ruhl; S Christy Sadreameli; Julian L Allen; Debra P Bennett; Andrew D Campbell; Thomas D Coates; Dapa A Diallo; Joshua J Field; Elizabeth K Fiorino; Mark T Gladwin; Jeffrey A Glassberg; Victor R Gordeuk; Leroy M Graham; Anne Greenough; Jo Howard; Gregory J Kato; Jennifer Knight-Madden; Benjamin T Kopp; Anastassios C Koumbourlis; Sophie M Lanzkron; Robert I Liem; Roberto F Machado; Alem Mehari; Claudia R Morris; Folasade O Ogunlesi; Carol L Rosen; Kim Smith-Whitley; Danna Tauber; Nancy Terry; Swee Lay Thein; Elliott Vichinsky; Nargues A Weir; Robyn T Cohen; Elizabeth S Klings
Journal:  Ann Am Thorac Soc       Date:  2019-09

4.  Murine models of sickle cell disease and beta-thalassemia demonstrate pulmonary hypertension with distinctive features.

Authors:  Paul W Buehler; Delaney Swindle; David I Pak; Mehdi A Fini; Kathryn Hassell; Rachelle Nuss; Rebecca B Wilkerson; Angelo D'Alessandro; David C Irwin
Journal:  Pulm Circ       Date:  2021-11-07       Impact factor: 2.886

Review 5.  Advances in the diagnosis and treatment of sickle cell disease.

Authors:  A M Brandow; R I Liem
Journal:  J Hematol Oncol       Date:  2022-03-03       Impact factor: 17.388

6.  HIV X4 Variants Increase Arachidonate 5-Lipoxygenase in the Pulmonary Microenvironment and are associated with Pulmonary Arterial Hypertension.

Authors:  Brandy E Wade; Kristi M Porter; Sharilyn Almodovar; Justin M Smith; Robert A Lopez-Astacio; Kaiser Bijli; Bum-Yong Kang; Sushma K Cribbs; David M Guidot; Deborah Molehin; Bryan K McNair; Laura Pumarejo-Gomez; Jaritza Perez Hernandez; Ethan A Salazar; Edgar G Martinez; Laurence Huang; Cari F Kessing; Edu B Suarez-Martinez; Kevin Pruitt; Priscilla Y Hsue; William R Tyor; Sonia C Flores; Roy L Sutliff
Journal:  Sci Rep       Date:  2020-07-16       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.